Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

NCT01907165 ↗

Phase 0 Completed 21 enrolled Washington University School of Medicine

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.

Timeline

Start: 2013-10-10
Primary completion: 2016-11-10
Completion: 2018-02-09

Publications

Karamanakos PN. Possible role for furazolidone in the treatment of glioblastoma multiforme. J BUON. 2013 Oct-Dec;18(4):1097. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Disulfiram	Small molecule	500 mg	Oral
Subject	Disulfiram	Small molecule	1000 mg	Oral
Background	Temozolomide	Small molecule	150 mg/m2	Oral
Background	Temozolomide	Small molecule	200 mg/m2	Oral

Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide

Summary

Timeline

Publications

Drugs

Indications